Aslan Pharmaceuticals Stock Total Debt
| ASLNDelisted Stock | USD 0.60 0.03 4.76% |
Aslan Pharmaceuticals fundamentals help investors to digest information that contributes to Aslan Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aslan Stock. The fundamental analysis module provides a way to measure Aslan Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aslan Pharmaceuticals stock.
Aslan |
Aslan Pharmaceuticals Company Total Debt Analysis
Aslan Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Aslan Pharmaceuticals Total Debt | 26.83 M |
Most of Aslan Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aslan Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Aslan Pharmaceuticals has a Total Debt of 26.83 M. This is 99.02% lower than that of the Biotechnology sector and 91.74% lower than that of the Health Care industry. The total debt for all United States stocks is 99.5% higher than that of the company.
Aslan Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aslan Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics of similar companies.Aslan Pharmaceuticals is currently under evaluation in total debt category among its peers.
Aslan Fundamentals
| Return On Equity | -4.27 | |||
| Return On Asset | -0.54 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 288.33 M | |||
| Shares Outstanding | 2.83 M | |||
| Shares Owned By Insiders | 0.14 % | |||
| Shares Owned By Institutions | 13.21 % | |||
| Number Of Shares Shorted | 306.56 K | |||
| Price To Earning | (11.50) X | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 0.94 X | |||
| Revenue | 12 M | |||
| Gross Profit | 79.82 M | |||
| EBITDA | (43.39 M) | |||
| Net Income | (44.22 M) | |||
| Cash And Equivalents | 78.12 M | |||
| Cash Per Share | 1.12 X | |||
| Total Debt | 26.83 M | |||
| Debt To Equity | 1.12 % | |||
| Current Ratio | 6.97 X | |||
| Book Value Per Share | (7.70) X | |||
| Cash Flow From Operations | (46.36 M) | |||
| Short Ratio | 1.85 X | |||
| Earnings Per Share | (16.00) X | |||
| Target Price | 72.0 | |||
| Number Of Employees | 35 | |||
| Beta | 1.4 | |||
| Market Capitalization | 1.7 M | |||
| Total Asset | 24.63 M | |||
| Retained Earnings | (321.07 M) | |||
| Working Capital | 11.02 M | |||
| Current Asset | 54.61 M | |||
| Current Liabilities | 5.15 M | |||
| Net Asset | 24.63 M |
About Aslan Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aslan Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Aslan Stock
Moving against Aslan Stock
| 0.89 | WMT | Walmart Aggressive Push | PairCorr |
| 0.83 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.76 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.76 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.75 | CSCO | Cisco Systems Aggressive Push | PairCorr |
The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |